Related Experiment Videos
Therapeutic options for acute myelogenous leukemia
1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4095, USA. ehestey@mdanderson.org
Cancer
|September 26, 2001
Summary
Most acute myelogenous leukemia (AML) patients, even newly diagnosed ones, benefit from investigational therapies due to variable outcomes with standard treatments. Research should focus on pilot trials for new AML treatments.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Review of general and novel therapeutic strategies for acute myelogenous leukemia (AML).
- Highlights the variability in outcomes for AML patients undergoing standard treatment.
Purpose of the Study:
- To describe new therapies for acute myelogenous leukemia (AML).
- To categorize AML patients for appropriate treatment selection based on prognostic factors.
Main Methods:
- Analysis of published literature.
- Inclusion of data from M. D. Anderson Cancer Center's acute leukemia database.
Main Results:
- Standard AML therapy outcomes are highly variable, influenced by prognostic factors like age, performance status, cytogenetics, and MDR1 expression.
- Most newly diagnosed AML patients fall into a category where investigational therapy is indicated.
- Investigational therapies target specific markers such as CD33 and MDR1.
Conclusions:
- The majority of newly diagnosed acute myelogenous leukemia (AML) patients should be considered for investigational treatment regimens.
- Clinical research in AML should prioritize pilot trials over large Phase III studies given the evolving therapeutic landscape.